Literature DB >> 7801601

Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates.

M Burnouf-Radosevich1, P Appourchaux, J J Huart, T Burnouf.   

Abstract

We have validated the use of two new regenerated multilayered structured cellulose membranes (BMM), Planova 15 N and Planova 35 N, with respective mean pore sizes of 15 and 35 nm, as a new filtration system to eliminate viruses in highly purified factor IX and factor XI concentrates. Virus spiking experiments indicated that single dead-end filtration on the membranes could remove more than 5.7-7.8 log10 of human immunodeficiency virus, bovine viral diarrhoea virus, porcine pseudorabies virus, reovirus type 3, and simian virus 40, as well as the small non-enveloped viruses, poliovirus Sabin type 1 and bovine parvovirus. In vitro control tests and animal studies (Wessler stasis model, rat hypotension model) of the two concentrates did not reveal any significant differences with the non-nanofiltered material. Viral filtration of plasma derivatives on porous polymeric membranes might be an essential step in the improvement of their viral safety.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7801601     DOI: 10.1111/j.1423-0410.1994.tb01647.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  12 in total

Review 1.  Downstream processing in the biotechnology industry.

Authors:  Manohar Kalyanpur
Journal:  Mol Biotechnol       Date:  2002-09       Impact factor: 2.695

Review 2.  Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Gabriele Calizzani; Fabio Candura; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

3.  Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests.

Authors:  Kati Hokynar; Päivi Norja; Harri Laitinen; Pekka Palomäki; Antoine Garbarg-Chenon; Annamari Ranki; Klaus Hedman; Maria Söderlund-Venermo
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

4.  Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study.

Authors:  F Bauduer; E de Raucourt; C Boyer-Neumann; M Trossaert; P Beurrier; A Faradji; J Peynet; J-Y Borg; P Chamouni; C Chatelanaz; C Henriet; F Bridey; J Goudemand
Journal:  Haemophilia       Date:  2015-03-26       Impact factor: 4.287

5.  First Report of Prevalence of Blood-Borne Viruses (HBV, HCV, HIV, HTLV-1 and Parvovirus B19) Among Hemophilia Patients in Afghanistan.

Authors:  Sayed Hamid Mousavi; Niloofar Khairkhah; Tina Delsouz Bahri; Ali Anvar; Alireza Azizi Saraji; Bita Behnava; Seyed Moayed Alavian; Ali Namvar
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

6.  Microscopic visualization of virus removal by dedicated filters used in biopharmaceutical processing: Impact of membrane structure and localization of captured virus particles.

Authors:  Jun Adan-Kubo; Muneo Tsujikawa; Kadue Takahashi; Tomoko Hongo-Hirasaki; Kaoru Sakai
Journal:  Biotechnol Prog       Date:  2019-07-03

Review 7.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

8.  Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity.

Authors:  Josephine H Cheng; Yu-Wen Wu; Chen-Yun Wang; Sharon S Wu; Cheum L Hong; Karen W Chan; Leo X Liao; Xisheng Cao; Bin Wang; Thierry Burnouf
Journal:  Blood Transfus       Date:  2021-08-04       Impact factor: 3.443

9.  Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.

Authors:  Herbert O Dichtelmüller; Lothar Biesert; Fabrizio Fabbrizzi; Rodrigo Gajardo; Albrecht Gröner; Ilka von Hoegen; Juan I Jorquera; Christoph Kempf; Thomas R Kreil; Dominique Pifat; Wendy Osheroff; Gerhard Poelsler
Journal:  Transfusion       Date:  2009-05-20       Impact factor: 3.157

10.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.